Jenna Sarvaideo, DO
- Froedtert Hospital
New & Established Patients Call
- DO - Doctor of Osteopathic Medicine
Dr. Sarvaideo completed her fellowship at the Medical College of Wisconsin in 2017. She then joined the Division of Endocrinology and Molecular Medicine as an Assistant Professor in 2017 and is currently the Associate Program Director for the Endocrinology Fellowship program. Dr. Sarvaideo is taking part in the Clinical Research Scholars Program with the Clinical and Translational Science Institute of Southeastern Wisconsin. She is involved in several national and international medical societies including the Endocrine Society, World Professional Association for Transgender Health, North American Menopause Society and Androgen Society. She serves on the Endocrine Society Transgender Research and Medicine Special Interest Group (SIG) Steering Committee.
Dr. Sarvaideo is the principal investigator for two clinical trials involving oral and sublingual estradiol and transgender women. She is involved in a quality improvement project in our MCW Inclusion Health Clinic. She also enjoys mentoring fellows, residents, and medical students. In 2019, she along with a medical student, were awarded an Endocrine Society Summer Research Fellowship Award. In 2020, she received a MCW Research Affairs Committee grant.
- BA, Bachelor's in Art History and Chemistry, New York University, New York, NY, 2008
- DO, New York Institute of Technology College of Osteopathic Medicine, Old Westbury, NY, 2012
- Lead reviewer, WPATH 26th Scientific Review Committee, World Professional Association for Transgender Health Associate, 07/17/2020 - 08/03/2020
- Program Director, Endocrinology Fellowship
Clinical Trials involving transgender women. Transgender medicine, male hypogonadism, menopause, PCOS, premature ovarian insufficiency, Turner Syndrome, Klinefelter Syndrome
09/2018 - Present, Sublingual Estradiol Versus Oral Estradiol in Transgender Women
Primary Aim. To establish the pharmacokinetics of sublingual estradiol versus oral estradiol in transgender women.
ClinicalTrials.gov Identifier: NCT04036500
Current, Coagulation Activation and Fibrinolysis with Sublingual versus Oral Estradiol in Transgender Women
Primary Aim 1: To measure coagulation system activation and fibrinolysis following sublingual versus oral estradiol administration in transgender women.
ClinicalTrials.gov Identifier pending
Current, The Utility of Monitoring Potassium in Transgender Women on Spironolactone.
(SenthilKumar G, Katunaric B, Bordas-Murphy H, Sarvaideo J, Freed JK.) Endocrinology. 2023 Apr 17;164(6) PMID: 37207450 PMCID: PMC10230790 SCOPUS ID: 2-s2.0-85163898622 05/20/2023
(Hayes H, Russell R, Haugen A, Nagavally S, Sarvaideo J.) J Endocr Soc. 2022 Oct 11;6(11):bvac133 PMID: 36267595 PMCID: PMC9562816 10/22/2022
(Sarvaideo J, Doll E, Tangpricha V.) Endocr Pract. 2022 Mar;28(3):353-354 PMID: 35074501 SCOPUS ID: 2-s2.0-85125482531 01/26/2022
(Doll E, Gunsolus I, Thorgerson A, Tangpricha V, Lamberton N, Sarvaideo JL.) Endocr Pract. 2022 Mar;28(3):237-242 PMID: 34781041 SCOPUS ID: 2-s2.0-85121347509 11/16/2021
(Sarvaideo JL, Clark J, Coan KE, Kravtsov O, Jacquart A, Knudson P, Maas D, Blank RD, Wang TS, Shaker JL.) AACE Clinical Case Reports. 1 May 2018;4(3):224-227 SCOPUS ID: 2-s2.0-85124183534 05/01/2018
(Hillard CJ, Beatka M, Sarvaideo J.) Compr Physiol. 2016 Dec 06;7(1):1-15 PMID: 28134998 PMCID: PMC5871916 SCOPUS ID: 2-s2.0-85020983619 01/31/2017
(Jenna L. Sarvaideo, DO1; Jennifer Clark, MD2; Kathryn E. Coan, MD3; Oleksandr Kravtsov, MD4; Amanda Jacquart, MS, CGC5; Paul Knudson, MD1; Diana Maas, MD1; Robert D. Blank, MD, PhD1; Tracy S. Wang, MD3; Joseph L. Shaker, MD1.) AACE Clinical Case Reports. https://doi.org/10.4158/EP171959.CR 05/01/2018